Form 4 for APRE Aprea Therapeutics, Inc.
Accepted 2023-01-30 00:00:00 ET · period of report 2023-01-30 · accession 0001104659-23-008064 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-01-30 | 2023-01-30 | APRE | Hamill John P. | CFO, SrVP, Prin. Fin, Acctg. Off | A - Grant | $0.00 | +269.9K | 269.9K | New | $0 |
| D | 2023-01-30 | 2023-01-30 | APRE | Hamill John P. | CFO, SrVP, Prin. Fin, Acctg. Off | A - Grant | $0.00 | +539.8K | 539.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-30 | A | A | 269,879 | $0.00 | 269,879 | D | — | — | (F1) These shares represent restricted stock units which were granted on January 30, 2023, and which will vest and be settled in common stock in three equal, annual installments beginning on January 30, 2024, January 30, 2025, and January 30, 2026, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. |
| 2 | Derivative | Employee Stock Option (Right to Buy) | 2023-01-30 | A | A | 539,758 | $0.00 | 539,758 | D | $0.5 · — to 2033-01-30 | 539,758 Common Stock | (F2) Twenty-five percent of these options vest on January 30, 2024, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. |